EAAT2 therefore appears to be a major target for the treatment of neurological diseases and addiction (by ceftriaxone), not only to combat glutamatergic neurotoxicity but also to prevent aberrant plasticity, which could be linked to cognitive deficits10, 11, 12. The gene discussed is SLC1A2; the disease is nervous system disorder.